Pfizer Inc. (NYSE: PFE) announced that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.

Genzyme Corp. (NASDAQ: GENZ) reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter.

Genzyme Corporation (Nasdaq: GENZ) announced results from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis.

Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.

In the first nine months of 2010 Group sales rose 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs. Excluding Tamiflu sales, which as expected were significantly lower than in the previous year, Group sales increased 6% (3% in Swiss francs, 7% in US dollars).

GlaxoSmithKline (GSK) provided further details about the strategic focus and development priorities of the company's unit dedicated to rare diseases. Following the announcement of a new alliance with Fondazione Telethon and Fondazione San Raffaele, Marc Dunoyer, Global Head of GlaxoSmithKline Rare Diseases, outlined his ambitions for the unit and its potential to deliver significant benefits to underserved patient groups worldwide.